Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

SANOFI : Combined General Shareholder Meeting of May 4, 2012

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/04/2012 | 07:35pm CEST
PRESS RELEASE Combined General Shareholder Meeting of May 4, 2012

? Shareholder approval of the corporate and consolidated financial statements for 2011

? Dividend of ?2.65 per share payable as of May 15, 2012

? Nomination of a new director

? Partial renewal of the Board of Directors

Paris, France - May 4, 2012 - Sanofi (EURONEXT : SAN et NYSE : SNY) announced its Combined General Shareholder Meeting was held today at the Palais des Congrès in Paris. All resolutions were adopted by its shareholders.

During the meeting, shareholders approved, among other resolutions, the corporate and consolidated financial statements for the year 2011. At the General Meeting, shareholders decided the distribution of a dividend in the amount of ?2.65 per share that will be detached on Euronext Paris on May 10, 2012 with payment as of May 15, 2012.
The General Meeting also approved the appointment of Mr. Laurent Attal as a director for a term of four years, i.e., until the General Meeting called to approve the financial statements for the year
2015. Finally, Mr. Uwe Bicker, Mr. Jean-René Fourtou, Ms. Claudie Haigneré, Ms. Carole Piwnica and Mr. Klaus Pohle have each been reappointed for a term of four years.
After the Shareholder Meeting, the Board of Directors is comprised as follows:

? Serge Weinberg, Chairman of the Board of Directors

? Christopher Viehbacher, Chief Executive Officer

? Laurent Attal

? Uwe Bicker

? Robert Castaigne

? Thierry Desmarest

? Lord Douro

? Jean-René Fourtou

? Claudie Haigneré

? Igor Landau

? Suet-Fern Lee

? Christian Mulliez

? Carole Piwnica

? Klaus Pohle

? Gérard Van Kemmel

During the meeting, the shareholders approved the appointment of statutory and deputy auditors. The shareholders additionally ratified the move of the registered headquarters of Sanofi to 54, rue La Boétie, 75008 Paris. During the Board of Directors session following the meeting, Mr. Klaus Pohle was renewed as Chairman of the Audit Committee.

1/2

The voting results will be available on the company's website (www.sanofi.com) in the coming days.
The audiocast of the Combined General Shareholder Meeting is available on the Company's website (www.sanofi.com).

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Contacts:

Media Relations Investor Relations

Jean-Marc Podvin Sébastien Martel

+ (33) 1 53 77 46 46 + (33) 1 53 77 45 45 mr@sanofi.com ir@sanofi.com

2/2

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
07:52p SANOFI : Regeneron and Sanofi to Host Investor Conference Call to Discuss DUPIXE..
06:27pDJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
06:12pDJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
05:56p SANOFI : and Regeneron Announce FDA Approval of Dupixent® (dupilumab), the First..
05:41p SANOFI : and Regeneron Announce FDA Approval of Dupixent® (dupilumab), the First..
05:41p SANOFI : Regeneron and Sanofi Announce FDA Approval of DUPIXENT® (dupilumab), th..
03:13a SANOFI : Ionis subsidiary Akcea files for $100 million stock offering
03/27 SANOFI : Disclosure of trading in own shares
03/27 VIVUS,INC. (NASDAQ : VVUS) Files An 8-K Entry into a Material Definitive Agreeme..
03/26 SANOFI INDIA : Quarterly results - sanofi india limited
More news
Sector news : Pharmaceuticals - NEC
11:08pDJSenator McCaskill Begins Probe of Prescription Opioid Marketing -- 2nd Update
11:05pDJSHIRE : Files 8K - Other Events
07:51pDJSenator McCaskill Begins Probe of Prescription Opioid Marketing -- Update
06:51pDJSenator McCaskill Begins Probe of Prescription Opioid Marketing
08:48aDJDuPont, Dow Get EU Approval for Merger -- WSJ
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
11:43a FDA OKs Regeneron and Sanofi's dermatitis med Dupixent
03/27 My Favorite Biotech Takeover Play
03/27 Sanofi gives up on ED med Stendra, returns rights to VIVUS
03/26 FOCUS ON EUROPE : Who Earned A $250M Performance Bonus Last Week?
03/24 Industry And Dark Pool Traders Bearish On Amgen
Advertisement
Financials (€)
Sales 2017 36 498 M
EBIT 2017 9 302 M
Net income 2017 5 592 M
Debt 2017 4 507 M
Yield 2017 3,65%
P/E ratio 2017 18,39
P/E ratio 2018 17,38
EV / Sales 2017 3,08x
EV / Sales 2018 2,94x
Capitalization 107 845 M
More Financials
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 82,2 €
Spread / Average Target -1,6%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias E. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI7.76%117 163
JOHNSON & JOHNSON8.91%341 030
ROCHE HOLDING LTD.8.73%220 248
PFIZER INC.5.23%203 546
NOVARTIS AG-0.47%195 735
MERCK & CO., INC.7.34%173 493
More Results